Zolpidem
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Zolpidem: From Insomnia to Sleep Disorder (Initiating and Maintaining Sleep)
One-Sentence Summary
Zolpidem is a non-benzodiazepine sedative-hypnotic (“Z-drug”) globally approved for insomnia, acting via selective GABA-A receptor modulation to facilitate rapid sleep onset and maintenance. The TxGNN model predicts it may be effective for Sleep Disorder, Initiating and Maintaining Sleep — closely aligning with its established global clinical use — with 0 registered clinical trials and 20 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not registered in the Philippines (globally approved for insomnia) |
| Predicted New Indication | Sleep Disorder, Initiating and Maintaining Sleep |
| TxGNN Prediction Score | 99.87% |
| Evidence Level | L1 |
| Philippines Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Zolpidem is an imidazopyridine derivative that acts as a positive allosteric modulator of the GABA-A receptor, selectively binding to subunits containing the α1 subunit. This selectivity enhances GABA-induced chloride ion influx, producing rapid sedative and hypnotic effects with significantly less anxiolytic and muscle-relaxant activity compared to classic benzodiazepines — making it particularly well-suited for sleep induction and maintenance. A landmark 2023 cryo-EM structural study published in Nature (PMID 37730991) directly confirmed the molecular pharmacology of this selective binding, providing high-quality mechanistic evidence at atomic resolution.
The predicted indication — difficulty initiating and maintaining sleep — is precisely the clinical profile for which zolpidem was developed and has been globally approved for decades. TxGNN’s near-perfect prediction score (99.87%) reflects the unusually strong biological and clinical alignment. This is therefore less a traditional “repurposing” discovery than a model validation: TxGNN correctly identifies zolpidem’s established therapeutic niche, which itself provides confidence in the overall model’s reliability.
From a regulatory perspective, zolpidem holds FDA approval in the United States and marketing authorization in numerous jurisdictions under brand names such as Ambien, Stilnox, and Zolsana. Its absence from the Philippines market represents a registration gap rather than a clinical evidence deficit — making it a compelling candidate for a local regulatory filing rather than a novel repurposing application requiring de novo clinical development.
Clinical Trial Evidence
Currently no related clinical trials registered in ClinicalTrials.gov or ICTRP matching this specific drug–indication query.
Context note: This query result reflects the structured database search for this Evidence Pack and does not represent the full insomnia trial history of zolpidem, which is extensive in published literature. The absence here is an artifact of the search scope, not a reflection of clinical evidence.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31880796 | 2019 | Phase 3 RCT | JAMA Network Open | Lemborexant vs. zolpidem extended-release in older adults with insomnia disorder; zolpidem ER served as active comparator, demonstrating established efficacy baseline in this high-risk population |
| 35843245 | 2022 | Network Meta-Analysis | Lancet | Comprehensive NMA of pharmacological interventions for insomnia in adults; estimated comparative effectiveness and safety for acute and long-term management across drug classes including zolpidem |
| 34121443 | 2021 | Network Meta-Analysis | J Managed Care & Specialty Pharmacy | NMA comparing lemborexant with multiple insomnia treatments including zolpidem ER; confirmed zolpidem’s benchmark efficacy status |
| 39879708 | 2025 | Phase 3 RCT (extension) | Sleep Medicine | Post-hoc analysis of sleep architecture in insomnia comorbid with mild obstructive sleep apnea (COMISA); zolpidem used as comparator, highlighting impact on REM sleep and cognition |
| 36472134 | 2023 | RCT | J Clinical Sleep Medicine | Compared lemborexant and zolpidem ER across polysomnography-defined insomnia subtypes (short vs. normal sleep duration); confirmed differential response profiles |
| 37477771 | 2023 | RCT (post-hoc) | CNS Drugs | Post-hoc analysis of wake bout number, duration, and distribution in insomnia patients; direct zolpidem comparison against daridorexant |
| 37549414 | 2023 | Narrative Review | J Family Practice | Updated clinical review of insomnia management; discusses zolpidem’s role, treatment sequencing, and cardiovascular/psychiatric outcomes of treating insomnia |
| 29487083 | 2018 | Review | Pharmacological Reviews | Comprehensive review of non-benzodiazepine hypnotics; covers zolpidem pharmacology, clinical applications, α1 selectivity, and safety concerns including cognitive impairment and dependence |
| 37730991 | 2023 | Structural Biology | Nature | Cryo-EM structures of native GABA-A receptor assemblies directly confirm the molecular pharmacology of zolpidem’s selective α1 subunit binding — foundational mechanistic evidence |
| 39374004 | 2024 | RCT | JAMA Internal Medicine | Masked taper with cognitive-behavioral therapy for benzodiazepine receptor agonist (including zolpidem) discontinuation in older adults; informs appropriate use and deprescribing strategy |
Philippines Market Information
Zolpidem is currently not registered in the Philippines. No marketing authorizations or product licenses are on record. There are no approved indications, dosage forms, or authorization numbers to report.
This represents a regulatory gap opportunity: zolpidem is a widely approved, mature drug globally, and local registration would primarily involve a dossier submission based on existing international approvals rather than new clinical trial requirements.
Safety Considerations
Please refer to the package insert for safety information.
Based on well-established global clinical experience, the following areas are known to require monitoring and should be incorporated into any safety dossier for regulatory submission:
- Dependence and abuse potential: Evidence of misuse and dependence documented in pharmacovigilance data (PMID 17324242); controlled substance scheduling applies in most jurisdictions
- Complex sleep behaviors: Sleepwalking, sleep-driving, and other parasomnias have been reported, particularly at higher doses
- CNS depression interactions: Risk of additive sedation with alcohol, opioids, and other CNS depressants
- Elderly and respiratory-compromised patients: Heightened risk of falls, psychomotor impairment, and respiratory depression
- Rebound insomnia: Upon abrupt discontinuation after prolonged use
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Zolpidem is supported by decades of global clinical evidence including multiple Phase 3 RCTs and Lancet-level network meta-analyses (Evidence Level L1), and TxGNN’s 99.87% prediction score directly confirms its established pharmacological profile for insomnia. The absence from the Philippines market is a registration gap, not a clinical uncertainty — the primary task is regulatory, not clinical development.
To proceed, the following is needed:
- Obtain a Philippines FDA (Food and Drug Administration of the Philippines) registration pathway assessment and determine whether a full or abridged dossier is required based on reference country approvals
- Compile a complete safety dossier: package insert warnings, contraindications, drug interaction data, and post-marketing pharmacovigilance records from reference jurisdictions
- Assess the local competitive landscape — identify other registered sedative-hypnotics in the Philippines and determine differentiation strategy (e.g., extended-release formulation, price positioning)
- Evaluate target patient population to determine preferred formulation (immediate-release vs. controlled-release) and appropriate prescribing restrictions
- Develop a risk management plan covering dependence potential, prescriber education, and elderly patient safety monitoring
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.